Bausch + Lomb Reports $1.137 Billion Revenue with 3% Growth in Q1 2025

Bausch + Lomb Corporation reported a revenue of $1.137 billion for the first quarter of 2025, marking a 3% increase from $1.099 billion in the same period last year. The growth was primarily driven by increased volumes across all segments, particularly in the Vision Care and Surgical segments, which saw product sales rise to $654 million and $214 million, respectively. However, the company also faced challenges, including a $19 million unfavorable impact from foreign currency fluctuations and a $11 million decrease in net realized pricing, particularly in its Pharmaceuticals segment, which remained flat at $267 million.

The company's net loss for the quarter was $212 million, compared to a loss of $167 million in the prior year, reflecting a significant decline in operating performance. Operating loss was reported at $83 million, a decrease of $89 million from an operating income of $6 million in Q1 2024. This downturn was attributed to increased selling, general, and administrative expenses, which rose to $563 million, and a $15 million inventory reserve charge related to the voluntary recall of certain enVista intraocular lenses (IOLs). The recall was initiated due to reports of toxic anterior segment syndrome (TASS) linked to specific lots of enVista IOL products.

Bausch + Lomb has been active in strategic acquisitions to bolster its product pipeline, including the recent acquisition of Whitecap Biosciences, which is developing therapies for glaucoma and geographic atrophy. The company also acquired Elios Vision and Trukera Medical in late 2024, enhancing its offerings in glaucoma treatment and dry eye diagnostics, respectively. These acquisitions are expected to contribute to future revenue growth, although the company has acknowledged the challenges posed by market conditions and pricing pressures.

Operationally, Bausch + Lomb reported a decrease in cash and cash equivalents, ending the quarter with $215 million, down from $325 million at the end of 2024. The company experienced net cash used in operating activities of $25 million, a significant decline from the $41 million generated in the same quarter last year. The decrease in cash flow was primarily due to the lower operating results and payments related to acquired in-process research and development costs. Looking ahead, Bausch + Lomb anticipates continued challenges from macroeconomic factors, including inflation and potential impacts from ongoing geopolitical conflicts, but remains focused on executing its strategic initiatives and improving operational efficiency.